For several decades, allogeneic hematopoietic cell transplantation (HCT) has remained an important tool in the management of patients with high-risk hematological malignancies. Reduced intensity conditioning regimens and advances in supportive care have improved the safety and accessibility of HCT and also increased the need for a deep and diverse stem cell donor pool. This demand has highlighted existing disparities in the unrelated donor registry, particularly for ethnic minorities, who face significant challenges in identifying HLA-matched adult donors.
For several decades, allogeneic hematopoietic cell transplantation (HCT) has remained an important tool in the management of patients with high-risk hematological malignancies. Reduced intensity conditioning regimens and advances in supportive care have improved the safety and accessibility of HCT and also increased the need for a deep and diverse stem cell donor pool. This demand has highlighted existing disparities in the unrelated donor registry, particularly for ethnic minorities, who face significant challenges in identifying HLA-matched adult donors. 1 The acceptance of umbilical cord blood and haploidentical grafts as viable 'alternative' donors has increased the options for these patients and now ensures that a donor can be identified for virtually all patients.
The utilization of haploidentical grafts represents appealing options owing to their ubiquity, low cost and donor availability for future lymphocyte accession compared with umbilical cord blood units. Haploidentical grafts, however, lack the long-term follow-up of traditional stem cell sources resulting in several areas where the optimal management strategy remains unknown. With a growing number of patients receiving HCTs from haploidentical sources in the United States and abroad, advancing the care of these patients represents an area of tremendous interest and clinical necessity. 2 Two decades ago, Beatty et al.
3 first reported their experience with HLA-disparate allografts. The patients had high rates of graft rejection and acute GVHD (aGVHD) that was nearly double the HLAmatched control group. Over the following decade, animal studies with post-HCT cyclophosphamide demonstrated encouraging results and gave way to two early-phase studies. [4] [5] [6] Mechanistically, post-transplant cyclophosphamide reduces the robust, alloantigendirected, naive T-lymphocyte population after stem cell infusion. 7 With posttransplant cyclophosphamide, the rates of aGVHD are substantially reduced. 8, 9 Subsequent work in 2008 confirmed minimal aGVHD; however, more than half of patients relapsed within 1 year and 2-year overall survival was a staggering 36%. 10 Parallel, multicenter trials were published 3 years later comparing double umbilical cord blood units with haploidentical grafts. After a median follow-up of 357 days, 45% of haploidentical patients relapsed and 62% were still alive 1 year after HCT.
11
The use of post-transplant cyclophosphamide was championed as a measure that advanced the safety of haploidentical HCT through diminished rates of aGHVD. GVHD, and the coveted GVL effects, are dogmatically linked and drive the long-term remissions seen in survivors. 12, 13 In spite of these low rates of aGVHD, improvements in the post-HCT management of these patients translated into improved clinical outcomes. 10, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Relapsed disease is a principal threat to these patients' longterm survival and affects 30-50% of our patients. [25] [26] [27] Relapse is driven by an aggressive disease biology that can be difficult and in many cases impossible to overcome. Underscoring the unique challenges of relapsing after a haploidentical HCT, a recent study showed that these patients had a shorter post-relapse survival than those who received traditional grafts. 27 The therapeutic options for these patients are diverse but remain largely ineffective in altering their long-term outcomes. Individuals who opt for aggressive therapies, in lieu of best supportive care, are generally offered salvage therapy followed by consolidation with donor lymphocyte infusion (DLI) or a second allogeneic HCT. Whenever possible, immunosuppressive therapy should be rapidly tapered to maximize the GVL effects.
SALVAGE THERAPY
Salvage chemotherapy is necessary for relapsed patients and results in CR rates of 40-60%. This percentage is substantially lower for patients who relapse within 1 year of treatment. 28, 29 There are no standard or universally agreed upon salvage regimens.
New immunotherapies exist for patients with relapsed lymphoid neoplasms and have improved the response rates. The anti-CD19 bi-specific T-cell engager blinatumomab induced a CR or CR with partial hematological recovery in 69% of patients with relapsed/refractory pre-B ALL in a phase II study. 30 Additional trials are ongoing. Many remain dubious that these responses will translate into long-term remissions. Blinatumomab, therefore, is generally regarded as a bridge to definitive therapy.
Clinical trials with chimeric antigen receptor T cells are ongoing and the early results of these studies have garnered tremendous excitement. The University of Pennsylvania group recently reported their experience with CD19-targeted chimeric antigen receptor T cells at the American Society of Hematology (ASH) annual meeting. More than half (29/53) of the patients remained in CR after a median follow-up of 10.6 months. In the 35 patients whose disease relapsed after allogeneic HCT, the cellular products were primarily of donor origin (median 100%) and there was no GVHD. 31 Their experience with chimeric antigen receptor T cells in patients relapsed after haploidentical and multiple allogeneic HCTs was similar (S Grupp, personal communication). A clinical challenge with this approach remains the management of cytokine release syndrome. With marked increases of pro-inflammatory cytokines, nearly all patients develop evidence of cytokine release syndrome. A quarter of patients developed symptoms that necessitated the use of the interleukin-6 antagonist tocilizumab, and 17% received tocilizumab plus corticosteroids. 31, 32 In patients with AML, the recent development of targeted therapies has led to renewed optimism, particularly for those with disease refractory to conventional cytotoxic chemotherapy. The FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation was discovered over a decade ago as a poor-risk molecular feature of AML. 33 The efficacy of the multikinase inhibitor midostaurin, which inhibits FLT3, was evaluated in the RATIFY (CALGB 10603) study, a randomized, placebocontrolled phase III trial. The results, presented during the plenary session of the 2015 ASH annual meeting, revealed a significant benefit in event-free survival and overall survival with midostaurin. 34 As a result, the US Food and Drug Administration has granted this agent Breakthrough Therapy designation. Studies evaluating gilteritinib (ASP2215), a separate FLT3 inhibitor, are ongoing.
Similarly, isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations are present in AML and are associated with an adverse prognosis making them attractive therapeutic targets. 35 At the Twentieth Annual Congress of the European Hematology Association, the results of two phase I studies of IDH1 and IDH2 inhibitors were presented. In patients treated with AG-120, an IDH1 inhibitor, 50% of evaluable subjects had an objective response: four patients entered a CR, two achieved a marrow CR, and six had stable disease. These responses lasted up to 5.7 months. 36 The IDH2 inhibitor, AG-221, also demonstrated favorable results. Objective responses were seen in 56% of patients, including six CRs, four marrow CRs and five patients in CR with incomplete count recovery. Responses to AG-120 were durable for up to 8.8 months. 37 Clinical trials represent an important opportunity for patients with relapsed/refractory hematological diseases to receive these new, novel therapies that may favorably alter their disease outcome. Enrolling patients on these studies may be challenging owing to strict exclusion criteria that disallow post-HCT patients. In spite of this, patients who are candidates for these trials should be encouraged to participate whenever possible.
CONSOLIDATION
The immune system recognizes and responds to antigen through a complex process that involves antigen presentation, adhesion and co-stimulation. By reducing antigen-presenting cell activation, downregulating cell adhesion molecules and evading surveillance owing to unique properties of the microenvironment, hematological malignancies elude immune surveillance and destruction. 38 In lymphoid diseases, leukemic blasts fail to induce allogeneic T-cell proliferation despite expression of major histocompatibility and cell adhesion molecules while defects in proliferation and interleukin-2 secretion are described in follicular lymphoma. 39, 40 Alternatively, tumor-mediated defects in the expression and function of natural killer cells and T cells are reported in AML. 41, 42 Relapse after HCT underscores the vagaries of these diseases, the challenges of obtaining long-term cures and the importance of bolstering the native or donor immune system in the relapsed setting.
The use of DLI in relapsed patients is an attractive option owing to the ease of lymphocyte acquisition, absent need for conditioning therapy and ability to titrate dosing. Some clinicians, however, may be reluctant to utilize DLI after haploidentical HCT relapse owing to concerns regarding GVHD. A recent study reported that only 3/48 of these patients received DLI, a pattern the authors concluded was associated with a shortened postrelapse survival. 27 A growing body of data indicates that DLI after haploidentical HCT is safe and effective. 43 A retrospective analysis demonstrated that chemotherapy with DLI resulted in a superior response rate and reduced incidence of relapse compared with chemotherapy alone. 44 In a second study, escalating doses of DLI were associated with an incidence of grades III-IV aGVHD of 15% and a cGVHD incidence of 7.5%. Approximately one-third of the patients on this study achieved a CR, and half of these were durable remissions. 45 A third study showed similar rates of GVHD and a response rate of 33-70%. 46 There are minimal long-term data on the durability of these responses and many remain skeptical that they will translate into long-term cures. In select patients, with formidable performance status and an available stem cell donor, a second allogeneic HCT (HCT2) may be considered as an option for long-term disease control. As relapsed disease tends to be biologically aggressive, it should come as no surprise that these outcomes are disappointing. In a study of 20 patients, HCT2 improved 1-year survival but failed to improve upon the overall survival at 2 years compared with patients treated with chemotherapy+/ − DLI. 47 In a second study, 24% of patients remained in remission after a median follow-up of 18 months. 48 Patients for whom HCT2 is considered should have an excellent performance status as the rate of transplant-related mortality approaches 45%. Elderly patients and, those receiving both HCTs within 6 months, are at the greatest risk of transplant-related mortality. [49] [50] [51] Since the early work on haploidentical HCT was published, transplant outcomes have improved significantly; however, the rate of relapse has fallen only incrementally. Relapse in this setting is associated with a shortened survival owing to an aggressive disease biology and few effective treatment strategies. Further work is needed in order better understand this patient population, the diseases that fuel these outcomes and the optimal management approaches for these patients.
